Literature DB >> 22922845

Polypoidal choroidal vasculopathy--an important diagnosis to make with therapeutic implications.

Gregg T Kokame.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22922845     DOI： 10.1097/IAE.0b013e3182695bf8

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-13       Impact factor: 3.117

2.  Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis).

Authors:  Gregg T Kokame
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

4.  Polypoidal Choroidal Vasculopathy in Highly Myopic Eyes with Elongated Axial Length.

Authors:  Gregg T Kokame; Elysse S Tom; Jessica G Shantha; Kyle N Kaneko
Journal:  Open Ophthalmol J       Date:  2017-11-21

5.  Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.

Authors:  Kunbei Lai; Ying Li; Lijun Zhou; Xiaojin Zhong; Chuangxin Huang; Fabao Xu; Lin Lu; Jian Ge; Chenjin Jin
Journal:  BMC Ophthalmol       Date:  2018-06-20       Impact factor: 2.209

6.  Combined therapy and antivascular endothelial growth factor monotherapies for polypoidal choroidal vasculopathy: A protocol for the systematic review and network meta-analysis of efficacy and safety.

Authors:  Yun Zhang; Xun Li; Xiaoye Chen; Zhaolun Cai; Zirong Zhang; You Tang; Tiancong Chang; Misha Chen; Meixia Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

7.  Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.

Authors:  Gregg T Kokame; James C Lai; Raymond Wee; Ryan Yanagihara; Jessica G Shantha; Julia Ayabe; Kelsi Hirai
Journal:  BMC Ophthalmol       Date:  2016-07-27       Impact factor: 2.209

8.  Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.

Authors:  Tock H Lim; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Won Ki Lee; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Ramune Patalauskaite; Philippe Margaron; Adrian Koh
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.